The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone
Pharmacokinetics and Safety in Healthy Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
28
Capsules, Oral, 600 mg, Q12h, Days 1-7
Capsules, Oral, 60 mg, Q24h, Days 1-7
Capsules, Oral, 200 mg, Q12h, Days 8-21
Ppd Development, Lp
Austin, Texas, United States
Pharmacokinetic parameters including AUC (TAU) Cmax and Cmin
Time frame: Day 21 pharmacokinetic assessment
To assess the safety, tolerability, and fractional excretion of sodium when BMS-709952 and BMS-650032 are co-administered
Time frame: Within 24 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Capsules, Oral, 30 mg, Q24h, Days 8-21